Six transmembrane epithelial antigen of the prostate 1 (STEAP1) was firstly investigated as a potential biomarker in prostate cancer and has been identified to be overexpressed in several types of cancers [6]. This evidence concerns the gene STEAP1 and Familial prostate cancer.